
    
      This is a multi-center, multi-national, prospective, randomized, double-blind,
      placebo-controlled study to evaluate the efficacy and safety/tolerability of faropenem
      medoxomil versus placebo in the treatment of subjects with a primary diagnosis of AECB. All
      subjects will have a pre-therapy sputum specimen obtained for culture and susceptibility
      testing.
    
  